Hjem
Per Eystein Lønnings bilde

Per Eystein Lønning

Professor
  • E-postPer.Lonning@uib.no
  • Telefon+47 55 97 20 10+47 55 97 20 27
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen

Professor Per Eystein Lønning har arbeidet sammenhengende innenfor kreftbehandling og forskning fra 1982. Han har fra 1990 vært overlege ved Kreftavdelingen, Haukeland Sykehus, og fra 1992 Professor ved Universitetet i Bergen.  Han leder Brystkreftgruppen ved Mohn kreftforskningslaboratorium. Gruppen, som i alt teller vel 20 medlemmer, arbeider hovedsakelig med brystkreft men og med andre kreftsykdommer, som tykktarmskreft og føflekkkreft. Gruppen består av forskere i Mohn Kreftforskningslaboratorium samt leger ved Kreftavdelingen, der flere i likhet med Lønning arbeider både med pasientbehandling og laboratorie-forskning. Lønning har arbeidet både med virkningsmekanismene for hormonell behandling samt cellegift ved brystkreft, og i tillegg arbeidet med kreftrisiko-faktorer. Hovedfeltet nå er mekanismer for resistens mot cellegift. 

Vitenskapelig artikkel
  • Vis forfatter(e) 2009. Molecular classes of breast cancer and their clinical relevance. Current Breast Cancer Reports. 183-189.
  • Vis forfatter(e) 2008. Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference? Anti-Cancer Drugs. S11-S13.
  • Vis forfatter(e) 2008. Endocrine treatment - "old-fashioned" therapy becoming redundant in an era of molecular medicine? Breast Care. 388-390.
  • Vis forfatter(e) 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research (NAR). 7267-7278.
  • Vis forfatter(e) 2007. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenetics & Genomics. 127-136.
  • Vis forfatter(e) 2006. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clinical and Experimental Immunology. 53-58.
  • Vis forfatter(e) 2006. The novel p21 polymorphism p21(G251A) is associated with locally advanced breast cancer. Clinical Cancer Research. 6000-6004.
  • Vis forfatter(e) 2006. Commentary on: Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer? Nature Clinical Practice Oncology. 356-357.
  • Vis forfatter(e) 2006. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer. 2968-75.
  • Vis forfatter(e) 2006. Antitumor efficacy improved by local delivery of species-specific endostatin. Journal of Neurosurgery. 118-128.
  • Vis forfatter(e) 2006. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes, Chromosomes and Cancer. 1155-1163.
  • Vis forfatter(e) 2005. Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin. Oncology Reports. 525-530.
  • Vis forfatter(e) 2005. Genomics-based prognosis and therapeutic prediction in breast cancer. The Journal of the National Comprehensive Cancer Network. 291-300.
  • Vis forfatter(e) 2005. Genomics in breast cancer - therapeutic implications? Nature Clinical Practice Oncology. 26-33.
  • Vis forfatter(e) 2005. Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: Clinical implication. Clinical Cancer Research. 878s-883s.
  • Vis forfatter(e) 2005. Aromatasehemmere i behandling av brystkreft. Tidsskrift for Den norske legeforening. 723-728.
  • Vis forfatter(e) 2005. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncologica. 23-31.
  • Vis forfatter(e) 2005. Aromatase inhibitors - socio-economical issues. Journal of Steroid Biochemistry and Molecular Biology. 137-142.
  • Vis forfatter(e) 2004. PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication. Experimental Cell Research. 58-73.
  • Vis forfatter(e) 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • Vis forfatter(e) 2003. TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clinical Cancer Research. 5582-5588.
  • Vis forfatter(e) 2003. Study of suboptimum treatment response: lessons from breast cancer. The Lancet. 177-185.
  • Vis forfatter(e) 2003. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America. 8418-8423.
  • Vis forfatter(e) 2003. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • Vis forfatter(e) 2003. Predictive value of tumour cell proliferation in locally advanced breast cancer treated neoadjuvant chemotherapy. European Journal of Cancer. 438-446.
  • Vis forfatter(e) 2003. Pharmacokinetics of third-generation aromatase inhibitors. Seminars in Oncology. 23-32.
  • Vis forfatter(e) 2003. Development of aromatase inhibitors and their pharmacologic profile. American Journal of Clinical Oncology. S3-S8.
  • Vis forfatter(e) 2003. Clinical pharmacokinetics of aromatase inhibitors and inactivators. Clinical Pharmacokinetics. 619-631.
  • Vis forfatter(e) 2002. The role of aromatase inactivators in the treatment of breast cancer. International Journal of Clinical Oncology. 265-270.
  • Vis forfatter(e) 2002. The TP53 Codon 72 Polymorphism May Affect the Function of TP53 Mutations in Breast Carcinomas but not in Colorectal Carcinomas. Cancer Epidemiology, Biomarkers and Prevention. 1684-1688.
  • Vis forfatter(e) 2002. The IGF-system in healthy pre- and postmenopausal women: relations to demographic variables and sex-steroids. Journal of Steroid Biochemistry and Molecular Biology. 95-102.
  • Vis forfatter(e) 2002. Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer. Breast Cancer Research and Treatment. 161-175.
  • Vis forfatter(e) 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proceedings of the National Academy of Sciences of the United States of America. 12963-12968.
  • Vis forfatter(e) 2002. Letrozole is more effective than anastrozole in suppressing total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients. American Journal of Oncology Review. 99-102.
  • Vis forfatter(e) 2002. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. Journal of Clinical Oncology. 751-757.
  • Vis forfatter(e) 2002. Aromatase inhibitors and inactivators for breast cancer therapy. Drugs & Aging. 277-298.
  • Vis forfatter(e) 2002. Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. Human Gene Therapy. 1115-1125.
  • Vis forfatter(e) 2001. The insulinlike growth factor system in human immunodeficiency virus infection: relations to immunological parameters, disease progression and antiretroviral therapy. Journal of Clinical Endocrinology and Metabolism. 227-233.
  • Vis forfatter(e) 2001. Pharmacokinetics and metabolism of formestane in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 39-47.
  • Vis forfatter(e) 2001. Microarrays in primary breast cancer ¿ lessons from chemotherapy studies. Endocrine-related cancer. Endocrine-Related Cancer. 259-263.
  • Vis forfatter(e) 2001. Influence of TP53 gene alterations and cErbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Research. 2505-2512.
  • Vis forfatter(e) 2001. Gene expression patterns of breast carcinomas distinguish tumor subclasses with potential clinical implications. Proceedings of the National Academy of Sciences of the United States of America. 10869-10874.
  • Vis forfatter(e) 2000. Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treatment Reviews. 205-227.
  • Vis forfatter(e) 2000. Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treatment Reviews. 205-227.
  • Vis forfatter(e) 2000. Screening breast cancer patients for ATM mutations found in Norwegian AT patients. British Journal of Cancer. 1650-1653.
  • Vis forfatter(e) 2000. Screening breast cancer patients for ATM mutations found in Norwegian AT patients. British Journal of Cancer. 1650-1653.
  • Vis forfatter(e) 2000. Pharmacology and clinical experience with exemestane. Experimental Opinion Investigation Drugs. 1897-1905.
  • Vis forfatter(e) 2000. Pharmacology and clinical experience with exemestane. Expert Opinion on Investigational Drugs. 1897-1905.
  • Vis forfatter(e) 2000. Molecular portraits of human breast tumours. Nature. 747-752.
  • Vis forfatter(e) 2000. Molecular portraits of human breast tumours. Nature. 747-52.
  • Vis forfatter(e) 2000. Molecular portraits of human breast tumours. Nature. 747-52.
  • Vis forfatter(e) 2000. Is there a growing role for endocrine therapy in the treatment of breast cancer? Drugs. 11-21.
  • Vis forfatter(e) 2000. Is there a growing role for endocrine therapy in the treatment of breast cancer? Drugs. 11-21.
  • Vis forfatter(e) 2000. Genetic variants of CYP19 (arometase) and breast cancer risk. Oncogene. 1329-1333.
  • Vis forfatter(e) 2000. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 1329-1333.
  • Vis forfatter(e) 2000. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 1329-1333.
  • Vis forfatter(e) 2000. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 1329-1333.
  • Vis forfatter(e) 2000. Exemestane in breast cancer: Current status and future directions. Clinical Breast Cancer. S28-S33.
  • Vis forfatter(e) 2000. Exemestane in breast cancer: Current status and future directions. Clinical Breast Cancer. S28-S33.
  • Vis forfatter(e) 2000. Endocrine therapy for treatment of breast cancer. Polish Oncology Journal of Nowotwory. 50-53.
  • Vis forfatter(e) 2000. Endocrine therapy for treatment of breast cancer. Polish Oncology. 50-53.
  • Vis forfatter(e) 2000. Clinico-pharmacological aspects of different hormone treatments. European Journal of Cancer. S81-S82.
  • Vis forfatter(e) 2000. Clinico-pharmacological aspects of different hormone treatments. European Journal of Cancer. S81-S82.
  • Vis forfatter(e) 2000. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology. 2234-2244.
  • Vis forfatter(e) 2000. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. Journal of Clinical Oncology. 2234-2244.
  • Vis forfatter(e) 2000. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology. 259-264.
  • Vis forfatter(e) 2000. A novel HPLC-RIA method for the simultaneous detection of estrone, estradiol and estrone sulphate levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology. 259-264.
  • Vis forfatter(e) 1999. TP53 as a predictor of response to chemotherpy in breast cancer. RSO Scientific Updates. 73-88.
  • Vis forfatter(e) 1999. TP53 as a predictor of response to chemotherapy in breast cancer. Review. European School of Oncology Scientific Updates. 73-88.
  • Vis forfatter(e) 1999. Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Letters. 73-77.
  • Vis forfatter(e) 1999. Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. Clinical Chemistry. 252-256.
  • Vis forfatter(e) 1999. Influence of TP53 gene alterations and Her-2 expression on the respons to treatment with doxorubicin in locally advanced breast cancer. (Abs. no. 227). Breast Cancer Research and Treatment.
  • Vis forfatter(e) 1999. CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1. Cancer Research. 2825-2828.
  • Vis forfatter(e) 1998. Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Vis forfatter(e) 1998. Pharmacological profiles of exemestane and formestane steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Research and Treatment. 45-52.
  • Vis forfatter(e) 1998. Pharmacological and clinical profile of anastrozole. Breast Cancer Research and Treatment. s53-s57.
  • Vis forfatter(e) 1998. Microencapsulated octreotide pamoate in advanced cancer. British Journal of Cancer. 14-20.
  • Vis forfatter(e) 1998. Microencapsulated Octreotide in Advanced Gastrointestinal and Pancreatic Cancer: a Phase I Study. British Journal of Cancer. 14-20.
  • Vis forfatter(e) 1998. Kinetics of plasma total homocysteine in patients receiving high-dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • Vis forfatter(e) 1998. Kinetics of plasma total homocysteine in patients receiving high- dose methotrexate therapy. Clinical Chemistry. 1987-1989.
  • Vis forfatter(e) 1998. Influence of treatment with onapristone on the IGF-system in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 159-163.
  • Vis forfatter(e) 1998. Influence of treatment with aminoglutethimide on plasma and red-blood-cell gluthatione status in breast cancer patients. Cancer Chemotherapy and Pharmacology. 46-52.
  • Vis forfatter(e) 1998. Influence of Droloxifene on Metastatic Breast Cancer as First Line Endocrine Treatment. Acta Oncologica. 365-368.
  • Vis forfatter(e) 1998. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breat cancer patients. Clinical Cancer Research. 2089-2093.
  • Vis forfatter(e) 1998. Changes in folate status as determined by reduction in total plasma homocysteine levels during leucovorin modulation of 5-fluorouracil therapy in cancer patients. Clinical Cancer Research. 2125-2128.
  • Vis forfatter(e) 1997. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. Journal of Steroid Biochemistry and Molecular Biology. 255-260.
  • Vis forfatter(e) 1997. Exemestane experience in breast cancer treatment. Journal of Steroid Biochemistry and Molecular Biology. 151-155.
  • Vis forfatter(e) 1997. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: A phase I study. Clinical Cancer Research. 1101-1108.
  • Vis forfatter(e) 1997. Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • Vis forfatter(e) 1997. Effects of hormones on the plasma level of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • Vis forfatter(e) 1997. Differential influence of carbamazepine and valproate monotherapy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • Vis forfatter(e) 1997. Different effects of carbamazepine and valproate monotheraphy on plasma levels of oestrone sulphate and dehydroepiandrosterone sulphate in male epileptic patients. Journal of Endocrinology. 307-312.
  • Vis forfatter(e) 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Vis forfatter(e) 1997. Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer. International Journal of Cancer. 138-140.
  • Vis forfatter(e) 1997. Anastrozole - A new generation in aromatase inhibition: Clinical pharmacology. Oncology. 11-14.
  • Vis forfatter(e) 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Vis forfatter(e) 1997. Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. British Journal of Cancer. 480-485.
  • Vis forfatter(e) 1996. Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: Clinical and endocrine effects. European Journal of Cancer. 789-792.
  • Vis forfatter(e) 1996. Spesific TP53 gene mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • Vis forfatter(e) 1996. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine. 811-814.
  • Vis forfatter(e) 1996. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clinical Cancer Research. 1515-1521.
  • Vis forfatter(e) 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Vis forfatter(e) 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Vis forfatter(e) 1996. Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; Clinical experience and parameters predicting outcome. Acta Oncologica. 5-8.
  • Vis forfatter(e) 1996. Pharmacology of new aromatase inhibitors. Breast. 202-208.
  • Vis forfatter(e) 1996. Insulin-like growth factors in breast cancer. Acta Oncologica. 19-22.
  • Vis forfatter(e) 1996. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. International Journal of Cancer, Predictive Oncology. 335-339.
  • Vis forfatter(e) 1996. Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Research and Treatment. 335-341.
  • Vis forfatter(e) 1996. Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-I IGFBP-3 in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 167-171.
  • Vis forfatter(e) 1996. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • Vis forfatter(e) 1996. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisatin and plasma oestrogen levels in post-menopausal women with breast cancer. British Journal of Cancer. 1286-1291.
  • Vis forfatter(e) 1996. Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF)I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. Journal of Clinical Endocrinology and Metabolism. 2216-2221.
  • Vis forfatter(e) 1996. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: A cross-over study. Clinical Endocrinology. 727-732.
  • Vis forfatter(e) 1995. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • Vis forfatter(e) 1995. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • Vis forfatter(e) 1995. Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • Vis forfatter(e) 1995. Insulin-like growth factors in breast and prostatic cancer. Endocrine-Related Cancer. 153-169.
  • Vis forfatter(e) 1995. Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • Vis forfatter(e) 1995. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • Vis forfatter(e) 1995. Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • Vis forfatter(e) 1995. Alterations in plasma IGF-I caused by hormone manipulation; of relevance to the mechanism of action and acquired resistance to endocrine treatment in breast cancer? Endocrine-Related Cancer. 127-130.
  • Vis forfatter(e) 1994. Primærbehandling av lokalavansert brystkreft med bruk av neoadjuvant kjemoterapi. Tidsskrift for Den norske legeforening. 668-670.
  • Vis forfatter(e) 1994. Pharmacokinetics of anti-endocrine agents. Cancer Surveys. S. 343-370.
  • Vis forfatter(e) 1993. Use of endocrine therapy to study the biology of breast cancer. Cancer Treatment Reviews. 65-77.
  • Vis forfatter(e) 1993. Plasma and urinary oestrogens in breast cancer patients on treatment with 4-hydroxy-androstenedione. British Journal of Cancer. 393-398.
  • Vis forfatter(e) 1993. Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
  • Vis forfatter(e) 1993. Pharmacokinetics of antiendocrine agents. Cancer Surveys. 343-370.
  • Vis forfatter(e) 1993. Dose response evaluation - Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio. Clinical Pharmacokinetics. 1-5.
  • Vis forfatter(e) 1993. Analysis of Phase I and Phase II metabolites of tamoxifen in breast cancer patients. Drug Metabolism And Disposition. 1119-1124.
  • Vis forfatter(e) 1992. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aramotisation in breast cancer patients. European Journal of Cancer. 1712-1716.
  • Vis forfatter(e) 1992. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. British Journal of Cancer. 692-697.
  • Vis forfatter(e) 1992. Prognostiske parametre ved lokalisert brystkreft. Prognostic parameters in early breast cancer. Tidsskrift for Den norske legeforening. 757-759.
  • Vis forfatter(e) 1992. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Vis forfatter(e) 1992. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Vis forfatter(e) 1992. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Vis forfatter(e) 1992. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Vis forfatter(e) 1992. Influence of tamoxifen on plasma levels of insulinelike growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
  • Vis forfatter(e) 1992. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
  • Vis forfatter(e) 1992. Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
  • Vis forfatter(e) 1992. Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
  • Vis forfatter(e) 1992. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patient on 4-hydroxyandrostenedione treatment. Breast Cancer Research and Treatment. 57-62.
  • Vis forfatter(e) 1992. Disposition of new endocrine drugs used in the treatment of advanced breast cancer. Clinical Pharmacokinetics. 327-358.
  • Vis forfatter(e) 1992. Disposition of new endocrine drugs used in the treatment of advanced breast cancer. Clinical Pharmacokinetics. 327-358.
  • Vis forfatter(e) 1992. Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. Clinical Pharmacokinetics. 327-358.
  • Vis forfatter(e) 1992. Aromatase inhibitors in malignant diseases of aging. Drugs & Aging. 530-545.
  • Vis forfatter(e) 1992. Aromatase activity, plasma oestradiol and their correlation with demographic indices in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 769-771.
  • Vis forfatter(e) 1991. Wie wirkungsvoll ist das Mammographie-Screening? Deutsche Medizinische Wochenschrift. 108-112.
  • Vis forfatter(e) 1991. Treatment of early breast cancer with conservation of the breast. Acta Oncologica. 779-792.
  • Vis forfatter(e) 1991. Treatment of breast cancer with aromatase inhibitors. Medicamentos de actualidad. 117-132.
  • Vis forfatter(e) 1991. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. British Journal of Cancer. 789-793.
  • Vis forfatter(e) 1991. Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemotherapy and Pharmacology. 367-372.
  • Vis forfatter(e) 1991. Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. Journal of enzyme inhibition (Print). 315-325.
  • Vis forfatter(e) 1991. Leser-Zuschriften - Mammographie-Screening. Deutsche Medizinische Wochenschrift. 636-637.
  • Vis forfatter(e) 1991. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2,6-dione ("pyridoglutethimide") in postmenopausal breast cancer patients. British Journal of Cancer. 887-894.
  • Vis forfatter(e) 1991. Distribution of tamoxifen and metabolites into brain tissue metastases in breast cancer patients. British Journal of Cancer. 641-645.
  • Vis forfatter(e) 1991. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. British Journal of Cancer. 641-645.
  • Vis forfatter(e) 1991. Distribution of Tamoxifen and meta-bolites into brain tissue and brain metastases in brain cancer patients. British Journal of Cancer. 641-645.
  • Vis forfatter(e) 1991. Aromatase inhibitors - future prospects. Int Congr Symp Series. 55-59.
  • Vis forfatter(e) 1990. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-2. A differential effect of megestrol acetate a medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin. Journal of Steroid Biochemistry. 105-109.
  • Vis forfatter(e) 1990. Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer-1. General findings. Journal of Steroid Biochemistry. 99-104.
  • Vis forfatter(e) 1990. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megastrol acetate in postmenopausal patients with advanced brea cancer. Cancer Chemotherapy and Pharmacology. 101-105.
  • Vis forfatter(e) 1990. Decreased serum concentrations of tamoxifen and its metabolites induced by aminogluethimide. Cancer Research. 5851-5857.
Vitenskapelig foredrag
  • Vis forfatter(e) 2012. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy.
  • Vis forfatter(e) 2011. GDPD5 expression correlates with choline metabolite profiles in human breast cancer.
  • Vis forfatter(e) 2010. Predicting long-term survival for breast cancer patients by HR MAS metabolic profiling during neoadjuvant chemotherapy.
  • Vis forfatter(e) 2010. Predicting long-term breast cancer survival in patients receiving neoadjuvant chemotherapy by MR metabolic profiling.
  • Vis forfatter(e) 1999. Neoadjuvant Treatment with Anastrozole ('ARIMIDEX') Causes Profound Suppression of Intra-Tumor Estrogen Levels.
  • Vis forfatter(e) 1999. Comparison of the effects of neoadjuvant 'Arimidex'(Anastrozole) on plasma and intra-tumor tissue estrogen levels in postmenopausalbreast cancer patients.
  • Vis forfatter(e) 1995. A randomized, double-blind, multicentre crossover trial to evaluate in vivo inhibition of aromatase by Arimidex (ZD1033) (1 mg and 10 mg PO OD) in postmenopausal women with breast cancer.
  • Vis forfatter(e) 1994. Treatment of postmenopausal breast cancer patients with the steroidal aromatase inhibitor Exemestane (FCE 24304).
  • Vis forfatter(e) 1994. Influence of megestrol acetate, aminoglutethimide and 4-hydroxyandrostendione on plasma IGF-I in breast cancer patients.
Vitenskapelig antologi/Konferanseserie
  • Vis forfatter(e) 2004. Expression profiling of breast cancer: From molecular portraits to clinical utility. John Wiley & Sons.
Sammendrag/abstract
  • Vis forfatter(e) 2010. Exploring chemoresistance in vivo; are we making progress. European Journal of Cancer. 155-155.
  • Vis forfatter(e) 2009. Proteomics analysis of tissue samples obtained before and during letrozole treatment in postmenopausal patients with locally advanced breast cancer. Cancer Research. 214S-214S.
  • Vis forfatter(e) 2009. DETERMINANTS OF INTRATUMOURAL OESTRADIOL (E2) CONCENTRATIONS IN POSTMENOPAUSAL BREAST CANCER: ROLES FOR OESTROGEN RECEPTOR (ER) AND 17B-HYDROXYSTEROID DEHYDROGENASE 7 (HSD17B7). Annals of Oncology. 51-52.
  • Vis forfatter(e) 2008. ER/PGR and prediction of response to hormonotherapy. Can we do better? Annals of Oncology. 29-29.
  • Vis forfatter(e) 2008. Are there any difference between third-generation aromatase inhibitors? European Journal of Cancer. 52-52.
  • Vis forfatter(e) 2008. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • Vis forfatter(e) 2007. Promotor hypermethylation of MGMT, RAR-beta2, RASSF1A and p16 in metastatic malignant melanoma. Proceedings of the American Association of Cancer Research. 684.
  • Vis forfatter(e) 2007. Biological lessons from adjuvant therapy. European Journal of Cancer. 25-25.
  • Vis forfatter(e) 2007. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • Vis forfatter(e) 2005. The SNP309HDM2 polymorphism is associated with chemoresistance and poor survival in breast cancers harboring mutations in the TP53 gene. Breast Cancer Research and Treatment. S160-S160.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) 2019. Constitutional mosaic epimutations - A hidden cause of cancer? Cell stress. 118-135.
  • Vis forfatter(e) 2016. Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer. Journal of Clinical Oncology. 1580-1583.
  • Vis forfatter(e) 2015. Estradiol measurement in translational studies of breast cancer. Steroids. 26-31.
  • Vis forfatter(e) 2014. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opinion on Pharmacotherapy. 681-700.
  • Vis forfatter(e) 2013. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene. 5315-5330.
  • Vis forfatter(e) 2013. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocrine-Related Cancer. R183-R201.
  • Vis forfatter(e) 2012. P53 and its molecular basis to chemoresistance in breast cancer. Expert opinion on therapeutic targets. S23-S30.
  • Vis forfatter(e) 2011. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Annals of Oncology. 503-514.
  • Vis forfatter(e) 2011. Exploring breast cancer estrogen disposition: The basis for endocrine manipulation. Clinical Cancer Research. 4948-4958.
  • Vis forfatter(e) 2010. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Review of Anticancer Therapy. 1825-1836.
  • Vis forfatter(e) 2010. Molecular basis for therapy resistance. Molecular Oncology. 284-300.
  • Vis forfatter(e) 2009. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? European Journal of Cancer. 527-535.
  • Vis forfatter(e) 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. European Journal of Pharmacology. 6-22.
  • Vis forfatter(e) 2009. Additive endocrine therapy for advanced breast cancer - back to the future. Acta Oncologica. 1092-1101.
  • Vis forfatter(e) 2008. Indications and limitations of third-gene ration aromatase inhibitors. Expert Opinion on Investigational Drugs. 723-739.
  • Vis forfatter(e) 2007. Breast cancer prognostication and prediction in the postgenomic era. Annals of Oncology. 1293-1306.
  • Vis forfatter(e) 2006. Aromatase inhibitors as adjuvant treatment of breast cancer. Critical Reviews in Oncology/Hematology. 53-61.
  • Vis forfatter(e) 2004. Aromatase inhibitors in breast cancer. Endocrine-Related Cancer. 179-189.

Se fullstendig oversikt over publikasjoner i CRIStin.

Kompetansefelt